Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43861   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase IIIb, open, randomized study to evaluate non-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella vaccine versus co-administration of GSK Biologicals’ Priorix™ and Varilrix™ in healthy children during their second year of life

    Summary
    EudraCT number
    		 2011-004485-15
    Trial protocol
    		 Outside EU/EEA  
    Global end of trial date
    27 May 2010

    Results information
    Results version number
    		 v2(current)
    This version publication date
    31 May 2023
    First version publication date
    30 Jul 2015
    Other versions
    		 v1
    Version creation reason
    • Correction of full data set
    Correction of full data set and alignment between registries.

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    110876
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT00751348
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    GlaxoSmithKline Biologicals
    Sponsor organisation address
    Rue de l’Institut 89, Rixensart, Belgium, B-1330
    Public contact
    Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
    Scientific contact
    Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    15 Oct 2010
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    27 May 2010
    Global end of trial reached?
    Yes
    Global end of trial date
    27 May 2010
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To demonstrate the non-inferiority of GSK Biologicals’ combined measles-mumps-rubella-varicella (MeMuRu-Oka) vaccine to Priorix and Varilrix vaccines administered as concomitant, separate injections in terms of measles, mumps, rubella, and varicella zoster virus (VZV) seroconversion rates 42-56 days after vaccination.
    Protection of trial subjects
    The subjects were observed closely for at least 30 minutes following the administration of vaccine(s), with appropriate medical treatment readily available in case of a rare anaphylactic reaction.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    16 Oct 2008
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Korea, Republic of: 474
    Worldwide total number of subjects
    474
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    474
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

    Period 1
    Period 1 title
    Overall Trial (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Priorix-Tetra Group
    Arm description
    		 Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix-Tetra vaccine at Day 0, administered subcutaneously in the deltoid region of the left upper arm.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Priorix-Tetra
    Investigational medicinal product code
    Other name
    MMRV
    Pharmaceutical forms
    Powder and solvent for solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    One dose of Priorix-Tetra vaccine was administered in the deltoid region of the left upper arm at Day 0.

    Arm title
    		 Priorix + Varilrix Group
    Arm description
    		 Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix vaccine together with one dose of Varilrix vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper arm, respectively.
    Arm type
    		 Active comparator

    Investigational medicinal product name
    Priorix
    Investigational medicinal product code
    Other name
    MMR
    Pharmaceutical forms
    Powder and solvent for solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    One dose of Priorix vaccine was administered in the deltoid region of the left upper arm at Day 0.

    Investigational medicinal product name
    Varilrix
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder and solvent for solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    One dose of Varilrix vaccine was administered in the deltoid region of the right upper arm at Day 0.

    Number of subjects in period 1
    		Priorix-Tetra Group Priorix + Varilrix Group
    Started
    313
    161
    Completed
    307
    159
    Not completed
    6
    2
         Consent withdrawn by subject
    5
    2
         Migration from study area
    1
    -

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Priorix-Tetra Group
    Reporting group description
    		 Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix-Tetra vaccine at Day 0, administered subcutaneously in the deltoid region of the left upper arm.

    Reporting group title
    Priorix + Varilrix Group
    Reporting group description
    		 Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix vaccine together with one dose of Varilrix vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper arm, respectively.

    Reporting group values
    		 Priorix-Tetra Group Priorix + Varilrix Group Total
    Number of subjects
    		 313 161 474
    Age categorical
    Units: Subjects
        In utero
    		 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0 0 0
        Newborns (0-27 days)
    		 0 0 0
        Infants and toddlers (28 days-23 months)
    		 313 161 474
        Children (2-11 years)
    		 0 0 0
        Adolescents (12-17 years)
    		 0 0 0
        Adults (18-64 years)
    		 0 0 0
        From 65-84 years
    		 0 0 0
        85 years and over
    		 0 0 0
    Age continuous
    Units: months
        arithmetic mean (standard deviation)
    		 12.4 ± 1.4 12.5 ± 1.65 -
    Gender categorical
    Units: Subjects
        Female
    		 128 76 204
        Male
    		 185 85 270
    Race/Ethnicity
    Units: Subjects
        Asian-East Asian Heritage
    		 313 159 472
        Asian-South East Asian Heritage
    		 0 2 2

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Priorix-Tetra Group
    Reporting group description
    		 Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix-Tetra vaccine at Day 0, administered subcutaneously in the deltoid region of the left upper arm.

    Reporting group title
    Priorix + Varilrix Group
    Reporting group description
    		 Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix vaccine together with one dose of Varilrix vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper arm, respectively.

    Primary: Number of subjects seroconverted for measles, mumps, rubella and varicella zoster virus (VZV) antibodies above the cut-off values

    		 Close Top of page
    End point title
    		 Number of subjects seroconverted for measles, mumps, rubella and varicella zoster virus (VZV) antibodies above the cut-off values
    End point description
    Seroconversion was defined as the appearance of antibodies [i.e. titer greater than or equal to (≥) the cut-off value] in the sera of subjects seronegative [i.e. titer below (<) cut-off value] before vaccination. Cut-off values were the following: Anti-measles concentration ≥ 150 milli-international units per milliliter (mIU/mL); Anti-mumps concentration ≥ 231 units per milliliter (U/mL); Anti-rubella concentration ≥ 4 international units per milliliter (IU/mL); Anti-VZV titer ≥ 1:4 dilution.
    End point type
    Primary
    End point timeframe
    At 42 days post-vaccination
    End point values
    		 Priorix-Tetra Group Priorix + Varilrix Group
    Number of subjects analysed
    300
    157
    Units: Subjects
        Anti-Measles (N=300; 156)
    294
    155
        Anti-Mumps (N=295; 154)
    262
    145
        Anti-Rubella (N=298; 157)
    297
    157
        Anti-VZV (N=283; 151)
    280
    151
    Statistical analysis title
    		 Non-inferiority - vaccine response to anti-measles
    Statistical analysis description
    Non-inferiority of Priorix-Tetra vaccine vs Priorix and Varilrix administered as concomitant vaccine 42-56 days after vaccination at Day 0 in terms of anti-measles seroconversion rates.
    Comparison groups
    Priorix-Tetra Group v Priorix + Varilrix Group
    Number of subjects included in analysis
    457
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [1]
    P-value
    		 < 0.05 [2]
    Method
    		 Fisher exact
    Parameter type
    		 Difference in percentage
    Point estimate
    -1.36
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -3.77
         upper limit
    		 1.66
    Variability estimate
    Standard deviation
    Notes
    [1] - Criterion for evaluation of non-inferiority: the lower limit (LL) of the two-sided standardized asymptotic 95% confidence interval (CI) for the group difference (Priorix-Tetra Group minus Priorix+Varilrix Group) in seroconversion rate for anti-measles was above -10%.
    [2] - The P-value for all reactogenicity comparisons was below (<) 0.05.
    Statistical analysis title
    		 Non-inferiority - vaccine response to anti-mumps
    Statistical analysis description
    Non-inferiority of Priorix-Tetra vaccine vs Priorix and Varilrix administered as concomitant vaccine 42-56 days after vaccination at Day 0 in terms of anti-mumps seroconversion rates.
    Comparison groups
    Priorix-Tetra Group v Priorix + Varilrix Group
    Number of subjects included in analysis
    457
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [3]
    P-value
    		 < 0.05 [4]
    Method
    		 Fisher exact
    Parameter type
    		 Difference in percentage
    Point estimate
    -5.34
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -10.4
         upper limit
    		 0.38
    Variability estimate
    Standard deviation
    Notes
    [3] - Criterion for evaluation of non-inferiority: the lower limit (LL) of the two-sided standardized asymptotic 95% confidence interval (CI) for the group difference (Priorix-Tetra Group minus Priorix+Varilrix Group) in seroconversion rate for anti-mumps was above -10%.
    [4] - The P-value for all reactogenicity comparisons was below (<) 0.05.
    Statistical analysis title
    		 Non-inferiority - vaccine response to anti-rubella
    Statistical analysis description
    Non-inferiority of Priorix-Tetra vaccine vs Priorix and Varilrix administered as concomitant vaccine 42-56 days after vaccination at Day 0 in terms of anti-rubella seroconversion rates.
    Comparison groups
    Priorix-Tetra Group v Priorix + Varilrix Group
    Number of subjects included in analysis
    457
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [5]
    P-value
    		 < 0.05 [6]
    Method
    		 Fisher exact
    Parameter type
    		 Difference in percentage
    Point estimate
    -0.34
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -1.88
         upper limit
    		 2.06
    Variability estimate
    Standard deviation
    Notes
    [5] - Criterion for evaluation of non-inferiority: the lower limit (LL) of the two-sided standardized asymptotic 95% confidence interval (CI) for the group difference (Priorix-Tetra Group minus Priorix+Varilrix Group) in seroconversion rate for anti-rubella was above -10%.
    [6] - The P-value for all reactogenicity comparisons was below (<) 0.05.
    Statistical analysis title
    		 Non-inferiority - vaccine response to anti-VZV
    Statistical analysis description
    Non-inferiority of Priorix-Tetra vaccine vs Priorix and Varilrix administered as concomitant vaccine 42-56 days after vaccination at Day 0 in terms of anti-varicella zoster virus (anti-VZV) seroconversion rates.
    Comparison groups
    Priorix-Tetra Group v Priorix + Varilrix Group
    Number of subjects included in analysis
    457
    Analysis specification
    Pre-specified
    Analysis type
    		 non-inferiority [7]
    P-value
    		 < 0.05 [8]
    Method
    		 Fisher exact
    Parameter type
    		 Difference in percentage
    Point estimate
    -1.06
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -3.07
         upper limit
    		 1.44
    Variability estimate
    Standard deviation
    Notes
    [7] - Criterion for evaluation of non-inferiority: the lower limit (LL) of the two-sided standardized asymptotic 95% confidence interval (CI) for the group difference (Priorix-Tetra Group minus Priorix+Varilrix Group) in seroconversion rate for anti-VZV was above -10%.
    [8] - The P-value for all reactogenicity comparisons was below (<) 0.05.

    Secondary: Antibody concentrations against measles

    		 Close Top of page
    End point title
    		 Antibody concentrations against measles
    End point description
    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
    End point type
    Secondary
    End point timeframe
    At 42-days post-vaccination
    End point values
    		 Priorix-Tetra Group Priorix + Varilrix Group
    Number of subjects analysed
    300
    156
    Units: mIU/mL
    geometric mean (confidence interval 95%)
        Anti-Measles (N=300; 156)
    4978.6 (4579.8 to 5412.1)
    3433.6 (3116.3 to 3783.2)
    No statistical analyses for this end point

    Secondary: Antibody concentrations against mumps

    		 Close Top of page
    End point title
    		 Antibody concentrations against mumps
    End point description
    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in units per milliliter (U/mL).
    End point type
    Secondary
    End point timeframe
    At 42-days post-vaccination
    End point values
    		 Priorix-Tetra Group Priorix + Varilrix Group
    Number of subjects analysed
    295
    154
    Units: U/mL
    geometric mean (confidence interval 95%)
        Anti-Mumps (N=295; 154)
    1012.3 (894.4 to 1145.7)
    934.3 (805.2 to 1084.1)
    No statistical analyses for this end point

    Secondary: Antibody concentrations against rubella

    		 Close Top of page
    End point title
    		 Antibody concentrations against rubella
    End point description
    Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
    End point type
    Secondary
    End point timeframe
    At 42 days post-vaccination
    End point values
    		 Priorix-Tetra Group Priorix + Varilrix Group
    Number of subjects analysed
    298
    157
    Units: IU/mL
    geometric mean (confidence interval 95%)
        Anti-Rubella (N=298; 157)
    63.4 (57.9 to 69.4)
    75.7 (68 to 84.3)
    No statistical analyses for this end point

    Secondary: Antibody titers against varicella viruses

    		 Close Top of page
    End point title
    		 Antibody titers against varicella viruses
    End point description
    Antibody titers were presented as geometric mean titers (GMTs).
    End point type
    Secondary
    End point timeframe
    At 42 days post-vaccination
    End point values
    		 Priorix-Tetra Group Priorix + Varilrix Group
    Number of subjects analysed
    283
    151
    Units: Titres
    geometric mean (confidence interval 95%)
        Anti-VZV (N=283; 151)
    134.1 (117 to 153.7)
    129.2 (109.8 to 152)
    No statistical analyses for this end point

    Secondary: Number of subjects with any and Grade 3 solicited local symptoms

    		 Close Top of page
    End point title
    		 Number of subjects with any and Grade 3 solicited local symptoms
    End point description
    Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Cry when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.
    End point type
    Secondary
    End point timeframe
    During the 4-day (Days 0-3) post-vaccination period
    End point values
    		 Priorix-Tetra Group Priorix + Varilrix Group
    Number of subjects analysed
    310
    159
    Units: Subjects
        Any Pain
    15
    10
        Grade 3 Pain
    0
    0
        Any Redness
    26
    21
        Grade 3 Redness
    0
    1
        Any Swelling
    5
    5
        Grade 3 Swelling
    0
    0
    No statistical analyses for this end point

    Secondary: Number of subjects with any, grade 3 and related solicited general symptoms

    		 Close Top of page
    End point title
    		 Number of subjects with any, grade 3 and related solicited general symptoms
    End point description
    Solicited general symptoms assessed were fever [defined as rectal temperature ≥38.0 degrees Celsius (°C)], rash, meningism and parotid gland swelling. Any= incidence of the specified symptoms regardless of intensity grade or relationship to study vaccine. Grade 3 fever= rectal temperature above (>) 39.5°C. Grade 3 rash= more than 150 lesions. Grade 3 meningism and parotid gland swelling= meningism/parotid gland swelling symptom which prevented normal everyday activities. Related = general symptom assessed by the investigator as causally related to the vaccination.
    End point type
    Secondary
    End point timeframe
    During the 43-day (Days 0-42) post-vaccination period
    End point values
    		 Priorix-Tetra Group Priorix + Varilrix Group
    Number of subjects analysed
    310
    159
    Units: Subjects
        Any temperature
    202
    82
        Grade 3 temperature
    53
    19
        Related temperature
    31
    12
        Any Rash
    33
    16
        Grade 3 Rash
    0
    0
        Related Rash
    3
    1
        Any Meningism
    2
    0
        Grade 3 Meningism
    0
    0
        Related Meningism
    0
    0
        Any Parotid gland swelling
    0
    0
        Grade 3 Parotid gland swelling
    0
    0
        Related Parotid gland swelling
    0
    0
    No statistical analyses for this end point

    Secondary: Number of subjects reporting any unsolicited adverse events (AEs)

    		 Close Top of page
    End point title
    		 Number of subjects reporting any unsolicited adverse events (AEs)
    End point description
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.
    End point type
    Secondary
    End point timeframe
    Within the 43-day (Days 0-42) post-vaccination period
    End point values
    		 Priorix-Tetra Group Priorix + Varilrix Group
    Number of subjects analysed
    313
    161
    Units: Subjects
        Any AE(s)
    194
    88
    No statistical analyses for this end point

    Secondary: Number of subjects with serious adverse events (SAEs)

    		 Close Top of page
    End point title
    		 Number of subjects with serious adverse events (SAEs)
    End point description
    Serious adverse events (SAEs) assessed include medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.
    End point type
    Secondary
    End point timeframe
    During the entire study period (from Day 0 up to Day 43 or Day 57)
    End point values
    		 Priorix-Tetra Group Priorix + Varilrix Group
    Number of subjects analysed
    313
    161
    Units: Subjects
        Any SAE(s)
    25
    12
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Solicited local: during the 4-day (Days 0-3) post-vaccination period. Solicited general symptoms and unsolicited AEs: during the 43-day (Days 0-42) post-vaccination period. SAEs: during the entire study period (from Day 0 up to Day 43 or 57).
    Adverse event reporting additional description
    The solicited local and general symptoms were only collected from those subjects who filled in their symptom sheets. The number of occurrences reported for solicited symptoms, adverse events, and serious adverse events were not available for posting. The number of subjects affected by each specific event was indicated as the number of occurrences.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    13.0
    Reporting groups
    Reporting group title
    Priorix-Tetra Group
    Reporting group description
    		 Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix-Tetra vaccine at Day 0, administered subcutaneously in the deltoid region of the left upper arm.

    Reporting group title
    Priorix + Varilrix Group
    Reporting group description
    		 Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix vaccine together with one dose of Varilrix vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper arm, respectively.

    Serious adverse events
    		 Priorix-Tetra Group Priorix + Varilrix Group
    Total subjects affected by serious adverse events
         subjects affected / exposed
    25 / 313 (7.99%)
    12 / 161 (7.45%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Injury, poisoning and procedural complications
    Road traffic accident
         subjects affected / exposed
    1 / 313 (0.32%)
    0 / 161 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Febrile convulsion
         subjects affected / exposed
    2 / 313 (0.64%)
    0 / 161 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    1 / 313 (0.32%)
    0 / 161 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    1 / 313 (0.32%)
    1 / 161 (0.62%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hepatitis
         subjects affected / exposed
    0 / 313 (0.00%)
    1 / 161 (0.62%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Acute tonsillitis
         subjects affected / exposed
    1 / 313 (0.32%)
    0 / 161 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchiolitis
         subjects affected / exposed
    3 / 313 (0.96%)
    2 / 161 (1.24%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchopneumonia
         subjects affected / exposed
    6 / 313 (1.92%)
    3 / 161 (1.86%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Croup infectious
         subjects affected / exposed
    2 / 313 (0.64%)
    0 / 161 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    5 / 313 (1.60%)
    6 / 161 (3.73%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis norovirus
         subjects affected / exposed
    1 / 313 (0.32%)
    0 / 161 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis rotavirus
         subjects affected / exposed
    2 / 313 (0.64%)
    0 / 161 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hand-foot-and-mouth disease
         subjects affected / exposed
    0 / 313 (0.00%)
    1 / 161 (0.62%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Herpangina
         subjects affected / exposed
    1 / 313 (0.32%)
    0 / 161 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Otitis media
         subjects affected / exposed
    1 / 313 (0.32%)
    0 / 161 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Otitis media acute
         subjects affected / exposed
    3 / 313 (0.96%)
    1 / 161 (0.62%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pharyngitis
         subjects affected / exposed
    5 / 313 (1.60%)
    1 / 161 (0.62%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pharyngotonsillitis
         subjects affected / exposed
    4 / 313 (1.28%)
    1 / 161 (0.62%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    1 / 313 (0.32%)
    1 / 161 (0.62%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rhinitis
         subjects affected / exposed
    1 / 313 (0.32%)
    0 / 161 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    0 / 313 (0.00%)
    1 / 161 (0.62%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Viral rash
         subjects affected / exposed
    1 / 313 (0.32%)
    0 / 161 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hypophagia
         subjects affected / exposed
    0 / 313 (0.00%)
    1 / 161 (0.62%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Iron deficiency
         subjects affected / exposed
    0 / 313 (0.00%)
    1 / 161 (0.62%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Priorix-Tetra Group Priorix + Varilrix Group
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    243 / 313 (77.64%)
    113 / 161 (70.19%)
    General disorders and administration site conditions
    Pain
         subjects affected / exposed [1]
    15 / 310 (4.84%)
    10 / 159 (6.29%)
         occurrences all number
    15
    10
    Redness
         subjects affected / exposed [2]
    26 / 310 (8.39%)
    21 / 159 (13.21%)
         occurrences all number
    26
    21
    Fever
         subjects affected / exposed [3]
    202 / 310 (65.16%)
    82 / 159 (51.57%)
         occurrences all number
    202
    82
    Rash
         subjects affected / exposed [4]
    33 / 310 (10.65%)
    16 / 159 (10.06%)
         occurrences all number
    33
    16
    Infections and infestations
    Upper respiratory tract infection
         subjects affected / exposed
    63 / 313 (20.13%)
    25 / 161 (15.53%)
         occurrences all number
    63
    25
    Nasopharyngitis
         subjects affected / exposed
    31 / 313 (9.90%)
    14 / 161 (8.70%)
         occurrences all number
    31
    14
    Gastroenteritis
         subjects affected / exposed
    28 / 313 (8.95%)
    13 / 161 (8.07%)
         occurrences all number
    28
    13
    Pharyngitis
         subjects affected / exposed
    27 / 313 (8.63%)
    10 / 161 (6.21%)
         occurrences all number
    27
    10
    Bronchitis
         subjects affected / exposed
    26 / 313 (8.31%)
    11 / 161 (6.83%)
         occurrences all number
    26
    11
    Bronchiolitis
         subjects affected / exposed
    21 / 313 (6.71%)
    11 / 161 (6.83%)
         occurrences all number
    21
    11
    Pharyngotonsillitis
         subjects affected / exposed
    21 / 313 (6.71%)
    10 / 161 (6.21%)
         occurrences all number
    21
    10
    Otitis media acute
         subjects affected / exposed
    13 / 313 (4.15%)
    9 / 161 (5.59%)
         occurrences all number
    13
    9
    Notes
    [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: For the analysis of solicited symptom, missing or non-evaluable measurements were not replaced. Therefore the analysis of the solicited symptoms based on the Total Vaccinated cohort included only subjects with documented safety data (i.e. symptom screen/sheet completed).
    [2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: For the analysis of solicited symptom, missing or non-evaluable measurements were not replaced. Therefore the analysis of the solicited symptoms based on the Total Vaccinated cohort included only subjects with documented safety data (i.e. symptom screen/sheet completed).
    [3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: For the analysis of solicited symptom, missing or non-evaluable measurements were not replaced. Therefore the analysis of the solicited symptoms based on the Total Vaccinated cohort included only subjects with documented safety data (i.e. symptom screen/sheet completed).
    [4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: For the analysis of solicited symptom, missing or non-evaluable measurements were not replaced. Therefore the analysis of the solicited symptoms based on the Total Vaccinated cohort included only subjects with documented safety data (i.e. symptom screen/sheet completed).

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 15:19:49 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA